Home > Cardiology > ACC 2021 > Electrophysiology > Etripamil nasal spray significantly improves PSVT-related symptoms

Etripamil nasal spray significantly improves PSVT-related symptoms

Presented By
Dr Bruce Stambler, Piedmont Heart Institute, USA
Conference
ACC 2021
Trial
Phase 3, NODE-301
Etripamil, a novel, L-type calcium channel blocker, significantly improved symptoms of paroxysmal supraventricular tachycardia (PSVT) and reduced the need for emergency interventions in the phase 3 trial NODE-301. Users reported higher levels of satisfaction and effectiveness than with a placebo [1]. Dr Bruce Stambler (Piedmont Heart Institute, GA, USA) reiterated the results of the phase 3 NODE-301 trial (NCT03464019), which were previously shared at the 2020 Heart Rhythm Society meeting. The multicentre NODE-301 study evaluated etripamil’s ability to terminate episodes of PSVT effectively and safely. Participants with a history of ECG-documented PSVT were randomised in a 2:1 fashion to self-administer either intranasal etripamil (n=107) or placebo (n=49) during an episode of PSVT. The study population had a median age of...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on